Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9050850 | 1.00 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL2369243 | 1.00 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL5360201 | 1.00 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL960818 | 1.00 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL26962278 | 1.00 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL8480025 | 1.00 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL9051516 | 1.00 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL19153077 | 0.98 | CA14 (0.41) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL3882477 | 0.92 | HDAC6 (0.39) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL99172 | 0.91 | HDAC1 (0.37) | HDAC6HDAC1HDAC2CA14L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9072734-B2 | Quaternary ammonium salt compounds | TEIJIN PHARMA LIMITED (JP) | 2015-07-07 | — | — | US | disclosed |
| EP-2426121-A1 | QUATERNARY AMMONIUM SALT COMPOUND | Teijin Pharma Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | TEIJIN PHARMA LIMITED (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | ADRB2, AGTR2, ADRB3 | HDAC6 489/4885HDAC1 583/4885HDAC2 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.